COMPARITIVE STUDY BETWEEN SERUM ANTI MULLERUAN HORMONE AND SERUM CA125 AS A PREDICTOR FOR THE SEVERITY OF ENDOMETRIOSIS IN INFERTILE WOMEN

Thesis Submitted for fulfillment of Master Degree on Gynecology and Obstetrics

By Khaled Nabil Ahmed Abd-Elrazik M.B.B.Ch. Cairo University 2003

Supervisors

Prof.Dr.Hisham Omar Kandil

Professor of Gynecology and Obstetrics Faculty of medicine – Cairo University

Dr.Dalia Youssef Mahmoud

Assistant Professor of Gynecology and Obstetrics Faculty of medicine – Cairo University

Dr.Osama Mahmoud Azmy

Assistant Professor of Gynecology and Obstetrics National research center

Cairo university 2009

Acknowledgment

Thanks to *God* the most gracious, the most merciful. I would like to express my deepest and most sincere gratitude to *Prof. Hisham Omar Kandil*, professor of obstetrics and gynecology, faculty of medicine Cairo University for his continuous supervision, valuable guidance, advice and encouragement.

I would also like to express my deepest thanks to **Dr. Dalia Youssef Mahmoud,** Assistant Professor of gynecology and obstetrics, Faculty of medicine, Cairo University, for her assistance and support throughout this work.

I would like to express my thanks to *Dr. Osama Mahmoud Azmy*, Assistant Professor of gynecology and obstetrics, National research center, for his great and invaluable help in this work.

I thank *Dr. Tamer Foad Taha*, lecturer of Gynecology and obstetrics, National research center, for his continuous help and support from the first step of this thesis.

Lastly, I want to express my greatest thanks to my *family* for their continuous support through all the hard and difficult times.

List of contents

| | Page |
|-------------------------------------|------|
| List of table | |
| List of figures | |
| List of abbreviations | |
| Abstract. | 1 |
| Introduction | 2 |
| Aim of the work | 4 |
| Review of literature | |
| Chapter (1): Endometriosis | 5 |
| Chapter (2): Anti mullerian hormone | 47 |
| Patients and methods | 78 |
| Results and Discussion. | 82 |
| Summary& Conclusion. | 97 |
| References | 101 |
| Arabic summary | |

LIST OF TABLES

| | | Page |
|-------------------|---|------|
| Table (1): | Differential Diagnosis of Endometriosis by Symptom | 16 |
| <u>Table (2):</u> | Potential roles of serum MIS/AMH in gynecology | 56 |
| <u>Table (3):</u> | Serum variables and follicle number assessed on two occasions | 58 |
| <u>Table (4):</u> | Comparison of ovarian reserve tests over time in normal fertile women | 60 |
| <u>Table (5):</u> | Classification of the patients according the type of infertility | 84 |
| <u>Table (6):</u> | Classification of the patients according to the severity of endometriosis according R-AFS classification of endometriosis | 85 |
| <u>Table (7):</u> | Classification of the patients according to the serum CA125 level | 86 |
| Table (8): | Classification of the patients according to serum level of AMH | 87 |
| <u>Table (9):</u> | Classification of the patients with first stage of endometriosis according to the level of AMH and its percentage. | 88 |
| <u>Table(10):</u> | Classification of the patients with second stage of endometriosis according to the level of AMH and its percentage. | 89 |
| <u>Table(11):</u> | Classification of the patients with third stage of endometriosis according to the level of AMH and its percentage. | 90 |

| <u>Table(12):</u> | Classification of the patients with fourth stage of endometriosis according to the level of AMH and its percentage | 91 |
|--------------------|---|----|
| <u>Table (13):</u> | Classification of the patients according to the severity of endometriosis and serum level of AMH | 92 |
| <u>Table (14):</u> | Classification of the percentage of the patients according to the severity of endometriosis and serum level of AMH. | 93 |
| <u>Table(15):</u> | Comparison between the mean value of serum level of CA125 and AMH | 94 |

LIST OF FIGURES

| | | J |
|--------------------|--|---|
| Figure (1): | Common locations of endometriosis within the abdomen and pelvis | |
| Figure (2): | Normal pelvis: uterus in anteversion giving a panoramic view of the pelvis | |
| Figure (3): | Endometriosis in an episiotomy scar | |
| Figure (4): | Superficial endometriosis of the ovary | |
| Figure (5): | perforated endometriosis cyst of the left ovary | , |
| Figure (6): | Endometriosis of the peritoneum | |
| <u>Figure (7):</u> | AMH expression in mouse ovaries | |
| Figure(8): | AMH is secreted by primary and preantral follicles | |
| Figure(9): | Serum AMH levels in normoovulatory women | |
| <u>Figure(10):</u> | Serum AMH levels are increased in normogonadotropic anovulatory infertile women | |
| <u>Figure(11):</u> | Classification of the patients according the type of infertility | |
| Figure(12): | Classification of the patients according to the severity of Endometriosis according R-AFS classification of endometriosis (A) and its percentage (B) | |
| <u>Figure(13):</u> | Classification of the patients according to the serum CA125 level (A) and its percentage (B) | |
| Figure(14): | Classification of the patients according of serum level of AMH (A) and its percentage (B) | |

| <u>Figure(15):</u> | Classification of the patients with first stage of endometriosis according to the level of AMH (A) and its percentage (B) | 88 |
|---------------------|--|----|
| <u>Figure(16):</u> | Classification of the patients with second stage of endometriosis according to the level of AMH (A) and its percentage (B) | 89 |
| <u>Figure(17):</u> | Classification of the patients with third stage of endometriosis according to the level of AMH and its percentage. | 90 |
| <u>Figure(18):</u> | Classification of the patients with fourth stage of endometriosis according to the level of AMH and its percentage. | 91 |
| <u>Figure (19):</u> | Classification of the percentage of the patients according to the severity of endometriosis and serum level of AMH | 93 |
| Figure(20): | Comparison between the mean value of serum level of CA125 and AMH | 94 |

LIST OF ABBREVIATIONS

| AFC | Antral Follicle Count. |
|-----------|---|
| AFS | American Fertility Society. |
| ALKs | Activin receptor Like protein Kinases. |
| AMH | Anti Müllerian Hormone. |
| AMHRII | Anti Müllerian Hormone type II Receptor. |
| ASRM | American Society for Reproductive Medicine. |
| BMP | Bone Morphogenetic Protien. |
| BMPs | Bone Morphogenetic Proteins. |
| BMI | Body Mass Index. |
| CA125 | Cancer Antigen 125. |
| СНО | Chinese Hamster Ovary. |
| СОН | Controlled Ovarian Hyperstimulation. |
| COX2 | Cyclooxygenase type |
| CT | Computed Tomography. |
| E2 | Estradiol. |
| ELISA | Enzyme Linked Immunosorbent Assay. |
| EMX2 | Empty spiracles homeobox 2 |
| FSH | Follicular Stimulating Hormone. |
| GCTs | Granulosa Cell Tumours. |
| GIFT | Gamete Intra Fallopian Transfer |
| GnRH | Gonadotrophin Releasing Hormone. |
| hCG | human Chorionic Gonadotrophin. |
| IVF | In Vitro Fertilization. |
| MIS | Müllerian Inhibiting Substance. |
| MR | Magnetic Resonance |
| NK | Natural Killer cell. |
| NSAIDs | Non Steroidal Anti Inflammatory Drugs. |
| OC | Oral Contraceptives. |
| OHSS | Ovarian Hyper Stimulation Syndrome. |
| PCOS | Poly Cystic Ovary Syndrome. |
| PCR | Polymerase Chain Reaction. |
| PF | Peritoneal Fluid. |

| PG | Prostaglandin. |
|--------|--|
| PMDS | Persistent Müllerian Duct Syndrome. |
| POF | Premature Ovarian Failure. |
| PP14 | Placental Protein 14. |
| PTEN | Phosphatase and Tensin homolog. |
| R-AFS | Revised American Society classification. |
| TATI | Tumor Associated Trypsin Inhibitor. |
| TGF- β | Transforming Growth Factor-Beta |
| US | Ultrasonography. |

دراسه تقارن بين نسبة AMH و نسبة CA125 في مصل الدم للتنبؤ بمدي إنتتشار داء بطانة الرحم الهاجره في السيدات العقيمات

رساله مقدمه من

الطبيب/ خالد نبيل أحمد عبد الرازق

بكالوريوس الطب والجراحه-جامعة القاهره

توطئه للحصول على درجة الماجستير

نے

أمراض النساء والتوليد

تحت اشراف

الأستاذ الدكتور/ هشام عمر قنديل

أستاذ أمراض النساء والتوليد

كلية الطب-جامعة القاهره

الأستاذ الدكتور/ داليا يوسف محمود

أستاذ مساعد أمراض النساء و التوليد

كلية الطب-جامعة القاهره

الأستاذ الدكتور/ أسامه محمود عزمى

أستاذ مساعد أمراض النساء و التوليد المركز القومي للبحوث

كلية الطب- جامعة القاهره

2009

Abstract

The aim of the study to evaluate the clinical value of the serum anti müllerian hormone (AMH) level in comparison with the serum cancer antigen 125 (CA125) level for diagnosing and determining the severity of endometriosis among infertile women. The sample of the study was 25 women undergoing laparoscopy for infertility. Endometriosis was diagnosed by direct visualization of implants by laparoscopy and classified into stages according to the Revised American Fertility Society (R-AFS) classification. Blood samples were drawn on cycle's days 5-12 and stored for subsequent analysis of AMH and CA125 levels and the value obtained was correlated with the presence or absence of endometriosis and the severity of the disease. The findings of this study suggested the possibility of using serum AMH for predicting the severity of endometriosis among infertile women.

Key words:

Endometriosis, Anti Müllerian Hormone (AMH), Cancer Antigen 125 (CA125).

Introduction

Endometriosis is a condition characterized by the presence of endometrial tissue in ectopic foci outside the uterus. The incidence of endometriosis in the general population has been variably assesses with the main consensus being 1/100 women (*Gleicher et al.*, 1995). In infertility population the incidence is higher with endometriosis accounting for the single most frequent cause of infertility (*Wellbery et al.*, 1999). Furthermore from 25% to 40% of women undergoing diagnostic laparoscopy because of infertility are found to have endometriosis (*Verkauf et al.*, 1987).

One of the difficulties in the diagnosis of endometriosis is that macroscopic and histologic demonstration of lesions in the abdominal cavity by laparotomy or laparoscopy is essential. Before establishment of diagnosis with surgery, a less invasive test is therefore important for initial screening of possible cases of endometriosis. Recent technical progress in transvaginal ultrasonography (*Dessole et al., 2003*) and magnetic resonance imaging (*Stratton et al., 2003*) improves diagnostic accuracy. These tools, together with symptoms and pelvic examination, appear to detect endometriosis with high sensitivity and specificity; however, current techniques are still limited in detecting small peritoneal lesions (*Eskenazi et al., 2001*). In addition to noninvasive imaging technologies, several biological markers for endometriosis can also be applicable to clinics like serum ca125 and ca19-9(*Gagne et al., 2003*).

CA 125 is a serum marker for monitoring patients with epithelial ovarian cancer (*Bast et al.*, 1998). Elevated CA 125 levels have been associated with a number of benign conditions and has been detected in several normal tissues including the endometrium and the lung. the more marked increases of Serum levels of CA125 in endometriosis is shown in women with stage III and IV, compared with Stage I and II. The value of CA 125 as a tool for monitoring treatment or disease progression has also been noted (*Vinatier et al.*, 2000).

In this study, a less invasive test is needed that can be used as the initial screening for cases of endometriosis. As women with endometriosis seem to have poor ovarian reserve with low oocyte and embryo quality. A meta-analysis of 22 studies evaluating in vitro fertilization outcomes found that patients with endometriosis had a pregnancy rate of nearly one half that of patients without endometriosis, with decreases in fertilization, implantation, and oocyte production rates (*Barnhart et al.*, 2002). Another recent study suggests that Minimal/mild endometriosis is associated with a decrease in the follicular ovarian reserve (*Lemos NA et al.*, 2008). Furthermore other studies suggest anti mullerian hormone as a novel measure of ovarian reserve (*De Vet et al.*, 2002).

In this study we prospectively assess the significance of serum AMH as a predictor for the severity of endometriosis in comparison with serum CA125.

Aim of the work:

To evaluate the clinical value of the serum anti müllerian hormone (AMH) level in comparison with the serum cancer antigen 125 (CA125) level for diagnosing and determining the severity of endometriosis among infertile women.

EPIDEMIOLOGY OF ENDOMETRIOSIS

Endometriosis can affect any woman, from premenarche to post menopause, regardless of her race, ethnicity or whether or not she has had children. Endometriosis often persists after menopause. Endometriosis in postmenopausal women is an extremely aggressive form of this disease characterized by complete progesterone resistance and extraordinarily high levels of aromatase expression (*Serdar and khaled, 2007*). 50% of postmenopausal women diagnosed with endometriosis had no previous history of the disease. Rarely, girls may have endometriosis before they even reach menarche (*Marsh and Laufer, 2006*).

Understanding the epidemiology of endometriosis has lagged behind other diseases because of methodological problems related to disease definition and control selection. Nevertheless, a better picture of the epidemiology of endometriosis has emerged over the past few decades. Prevalence of the disease in clinic populations varies from about 4% occurrence of largely asymptomatic endometriosis found in women undergoing tubal ligation to 50% of teenagers with intractable dysmenorrhea (*Cramer and Missmer, 2002*).

Prevalence estimates endometriosis in clinic populations vary by diagnosis. The prevalence of largely asymptomatic endometriosis found in women undergoing tubal ligation was about 4%, ranging from 1 % to 7%. In a multicenter study of infertility, endometriosis was diagnosed in 17% of women with primary infertility, but in other series the prevalence varied from about 9% to 50%. As regard the pelvic pain, endometriosis was diagnosed in 8% of cases while other